Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
RX

NASDAQ · RXST

RxSight, Inc.

Healthcare · Medical - Devices

$6.25

Up+$0.16 (+2.63%)

Updated Aug 22, 2026, 12:04 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
539.04M
P/E ratio
-16.56
Dividend yield
0.00%
52-week range
$4.48 – $13.22
Volume
1.54M
Avg. volume
777.3K

Price performance

RXST price history

1M range · 21 trading sessions · Daily adjusted prices

RXST closed at $6.25 after 21 trading sessions, up 20.42% for the selected period.

Last close
$6.25
Period change
+20.42%
Period low
$5.19
Period high
$7.06
Daily close
View OHLC price history
RXST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$6.10$6.31$6.00$6.251.54M
Aug 20, 2026$6.09$6.245$5.945$6.09663K
Aug 19, 2026$6.37$6.66$6.095$6.16622.53K
Aug 18, 2026$6.38$6.67$6.26$6.37712.54K
Aug 17, 2026$6.80$6.87$6.385$6.48657.08K
Aug 14, 2026$7.04$7.095$6.87$6.89488.39K
Aug 13, 2026$7.06$7.155$6.89$7.01703.01K
Aug 12, 2026$6.98$7.185$6.88$7.06811.26K
Aug 11, 2026$6.53$7.22$6.51$7.041.65M
Aug 10, 2026$6.26$6.585$6.245$6.571.15M
Aug 7, 2026$6.03$6.295$5.94$6.26627.7K
Aug 6, 2026$6.00$6.13$5.43$6.081.34M
Aug 5, 2026$6.17$6.3835$6.01$6.29903.43K
Aug 4, 2026$6.28$6.43$6.155$6.25645.89K
Aug 3, 2026$6.10$6.335$6.065$6.291.23M
Jul 31, 2026$6.08$6.115$5.86$6.01540.87K
Jul 30, 2026$6.14$6.22$5.9329$6.08509.87K
Jul 29, 2026$6.00$6.225$5.84$6.13935.66K
Jul 28, 2026$5.64$6.07$5.64$6.051.33M
Jul 27, 2026$5.25$5.68$5.25$5.64984.1K
Jul 24, 2026$5.40$5.465$5.055$5.19843.49K

Latest RXST news

The latest Smart Investors Daily articles mentioning RXST.

Stock researchCompany · Overview

RXST research

Overview

Company profile and research snapshot.

Company profile

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
RXST recent ratings
DateFirmRatingTarget
Aug 10, 2026StifelHold—
Aug 6, 2026UBSNeutral—
Jul 7, 2026NeedhamBuy—
Jul 7, 2026B of A SecuritiesUnderperform—
May 7, 2026Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 13, 2026

Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By